Novo Nordisk Ozempic Lawsuit: 2026 Legal Update

Quick Answer Box

• What this case is: A federal mass tort consolidated under MDL No. 3094 in the Eastern District of Pennsylvania, alleging Novo Nordisk failed to adequately warn patients that Ozempic and related semaglutide drugs can cause severe, sometimes permanent gastrointestinal injuries including gastroparesis and intestinal obstruction.
• Who qualifies: Patients who used Ozempic, Wegovy, or other semaglutide formulations and were subsequently diagnosed with gastroparesis, intestinal ileus, intestinal obstruction, cyclic vomiting syndrome, or required hospitalization for related complications.
• What it may be worth: Individual claim values vary by injury severity. Tier 1 catastrophic injuries (requiring surgery or resulting in permanent disability) are estimated in the range of $250,000 to $1,000,000+. Moderate injury claims range from $50,000 to $250,000. No global settlement has been announced as of early 2026.

Case Snapshot

The Novo Nordisk Ozempic lawsuit is one of the largest active pharmaceutical mass torts in the United States. Tens of thousands of patients who took semaglutide-based drugs for diabetes or weight management now allege those drugs caused permanent stomach and intestinal damage that Novo Nordisk knew about and failed to disclose.

The litigation is centralized in federal court in Philadelphia. Judge Gene E.K. Pratter oversees pretrial proceedings for what has grown into a docket exceeding 10,000 individual complaints by early 2026.

A related guide: AI Lawsuit News 2026: Cases, Claims, Who Qualifies

The core legal theory is failure to warn. Plaintiffs argue Novo Nordisk's labeling was materially deficient about the risk and severity of gastroparesis and related gastrointestinal conditions.

No global settlement has been reached. Bellwether trials, which function as test cases that reveal how juries respond to evidence on both sides, are still in the discovery and selection phase. The outcome of those trials will shape settlement negotiations significantly.

Novo Nordisk Ozempic Lawsuit: What the Case Is Actually About

The Novo Nordisk Ozempic lawsuit centers on a single legal claim: Novo Nordisk sold a dangerous drug without giving patients adequate warning about its most serious risks.

Ozempic, approved by the FDA in 2017 for type 2 diabetes management, belongs to a class of drugs called GLP-1 receptor agonists. These drugs work by slowing gastric emptying, which reduces blood sugar spikes and suppresses appetite.

Plaintiffs allege that same mechanism, slowing the digestive system, caused gastroparesis and intestinal obstruction in a subset of patients. They further allege Novo Nordisk had internal data suggesting this risk was underreported to regulators and patients.

Key allegations in the operative complaints:

• Novo Nordisk knew of gastroparesis risk before full commercialization of Ozempic
• The FDA-approved label did not clearly disclose the risk of permanent stomach paralysis
• Novo Nordisk's aggressive marketing obscured safety signals in post-market surveillance
• Plaintiffs were not warned that GI complications could persist permanently after discontinuing the drug

*Attorney Insight: Attorneys handling these claims note that the failure-to-warn theory in pharmaceutical cases often turns on what the manufacturer knew and when, making internal company documents obtained through discovery the centerpiece of pretrial litigation strategy.*

Litigation Watch: The core of this case is not whether Ozempic works but whether Novo Nordisk adequately disclosed that it can permanently disable the digestive system in some patients.

Ozempic Lawsuit 2026: Where the Litigation Stands Right Now

By early 2026, the Ozempic lawsuit has entered a critical phase. The JPML consolidated all federally filed cases into MDL 3094 through a transfer order executed in February 2024.

Since then, Judge Pratter has presided over aggressive pretrial management. That includes coordinating discovery from Novo Nordisk's internal files, establishing a plaintiff fact sheet protocol, and beginning the process of selecting bellwether cases.

*Attorney Insight: Attorneys familiar with MDL timelines note that bellwether trial dates in complex pharmaceutical MDLs typically emerge 18 to 30 months after consolidation, placing a potential first trial in late 2025 or 2026 if discovery proceeds without major delays.*

The number of filed complaints is accelerating. Projections from litigation tracking firms suggested the docket could exceed 25,000 cases by year-end 2026 if injury reporting patterns hold.

Ozempic MDL 3094: How the Multidistrict Litigation Works

MDL No. 3094 is the formal federal mechanism consolidating Ozempic and semaglutide injury claims from across the country into one pretrial court.

The Judicial Panel on Multidistrict Litigation, known as the JPML, issued the transfer order assigning all qualifying federal complaints to Judge Gene E.K. Pratter in the Eastern District of Pennsylvania. Philadelphia was selected as the transferee district because of its established capacity for complex pharmaceutical MDLs.

Understanding how an MDL functions is essential before filing. The MDL does not merge all cases into a single class action. Each plaintiff retains an individual case.

How MDL 3094 works in practice:

• All pretrial matters (discovery, motions, case management) happen in Philadelphia under Judge Pratter
• Individual cases are not tried in the MDL; after pretrial proceedings, cases may be remanded to the plaintiff's home district for trial
• Bellwether trials are selected cases tried within the MDL to test arguments and evidence before a jury
• Settlement negotiations typically follow bellwether outcomes

*Attorney Insight: Attorneys handling these claims explain that filing into MDL 3094 is not the same as joining a class action. Each plaintiff's individual damages are preserved and litigated separately.*

Ozempic Gastroparesis Lawsuit: The Primary Injury Category

Gastroparesis is the most frequently cited injury in the Ozempic litigation, appearing in a substantial majority of individual complaints filed in MDL 3094.

Gastroparesis means the stomach cannot empty properly. The muscle contractions that normally move food through the digestive tract are significantly weakened or absent. Symptoms include severe nausea, vomiting, bloating, and chronic pain.

In the context of semaglutide use, plaintiffs allege that the drug's mechanism, deliberately slowing gastric motility, triggered permanent gastroparesis that persisted long after discontinuing Ozempic.

Gastroparesis severity scale as relevant to litigation:

The FDA updated Ozempic's label in September 2023 to add a warning about ileus, a type of intestinal paralysis. Plaintiffs argue this label update confirms that the prior labeling was deficient and that Novo Nordisk acted too late.

*Attorney Insight: Attorneys handling these claims point to the FDA's 2023 label update as central evidence that the prior labeling was inadequate, supporting the core failure-to-warn theory.*

Ozempic Intestinal Obstruction Lawsuit: A Separate Injury Track

Intestinal obstruction is a distinct injury category within the broader Ozempic litigation, affecting a significant subset of plaintiffs independent of those diagnosed with gastroparesis.

An intestinal obstruction occurs when the normal flow of intestinal contents is physically blocked. In the GLP-1 drug context, plaintiffs allege that extreme slowing of intestinal motility caused bowel contents to accumulate, leading to partial or complete obstruction requiring emergency surgical intervention.

Some complaints also allege intestinal ileus, a closely related condition where the bowel temporarily ceases to function, often requiring hospitalization and, in severe cases, bowel resection surgery.

Distinguishing intestinal obstruction claims from gastroparesis claims:

• Gastroparesis primarily affects the stomach; intestinal obstruction affects the small or large intestine
• Obstruction cases often involve emergency surgery, which elevates damages
• Intestinal injury plaintiffs may face different medical records requirements during plaintiff fact sheet submissions
• Some plaintiffs experienced both conditions sequentially, creating compound injury profiles

*Attorney Insight: Attorneys handling these claims note that surgical intervention records and post-operative complications significantly affect the damages calculation in intestinal obstruction cases, making complete medical records a priority in case evaluation.*

Litigation Watch: Gastroparesis and intestinal obstruction claims collectively represent the two primary injury tracks in MDL 3094, with surgical cases carrying the highest individual damages potential.

Ozempic Failure to Warn: The Core Legal Theory Explained

Failure to warn is the legal doctrine at the center of the Novo Nordisk Ozempic lawsuit.

Under federal and state product liability law, a drug manufacturer has a duty to warn prescribing physicians and, in some circumstances, patients directly, about known material risks associated with their product. Failing to provide adequate warnings renders the manufacturer liable for resulting injuries.

In the Ozempic litigation, plaintiffs are asserting that:

• The risk of gastroparesis was a known or knowable risk at the time of commercialization
• The FDA-approved label did not adequately characterize the severity or permanence of that risk
• Novo Nordisk's marketing communications further minimized GI risk signals
• Had adequate warnings been provided, prescribing physicians would have counseled patients differently or declined to prescribe in certain risk profiles

The learned intermediary doctrine complicates this analysis. In most states, a drug manufacturer's duty to warn runs to the physician, not the patient directly. Plaintiffs must show the prescribing physician was not adequately informed.

*Attorney Insight: Attorneys handling these claims advise that states vary significantly in how they apply the learned intermediary doctrine, making state-specific legal strategy a critical factor in how individual complaints are drafted.*

Ozempic Side Effects Lawsuit: Which Conditions Qualify

The ozempic side effects lawsuit is not limited to gastroparesis and intestinal obstruction. Multiple GI injury categories appear in filed complaints, though courts and plaintiff leadership have generally tiered injury severity for litigation management purposes.

Qualifying injury categories in MDL 3094 (as of early 2026):

Mere nausea or vomiting that resolved without medical intervention is generally not sufficient to sustain a claim in MDL 3094. Courts expect documented injuries that required professional medical treatment.

*Attorney Insight: Attorneys handling these claims note that the plaintiff fact sheet process in MDL 3094 is demanding, requiring precise medical documentation for each qualifying injury, and that incomplete submissions result in case management orders requiring supplementation.*

Who Qualifies for the Ozempic Lawsuit?

A patient may qualify for the Ozempic lawsuit if they meet a specific set of factual and medical criteria that align with the operative complaints filed in MDL 3094.

Eligibility is not automatic for every person who experienced side effects. Courts and plaintiff leadership are focused on cases with documented, clinically significant injuries.

Core eligibility criteria:

• Confirmed use of Ozempic (semaglutide), Wegovy (semaglutide), or Rybelsus (semaglutide) at any point
• A formal medical diagnosis of gastroparesis, intestinal obstruction, ileus, cyclic vomiting syndrome, or a closely related GI injury
• Diagnosis made by a treating physician with supporting diagnostic testing (gastric emptying study, imaging, or endoscopy)
• Medical documentation showing the condition required professional treatment (ER visit, hospitalization, or ongoing specialist care)
• A causal timeline consistent with drug use preceding the onset of symptoms

*Attorney Insight: Attorneys handling these claims note that the causal timeline, meaning the onset of symptoms during or shortly after Ozempic use, is among the most scrutinized elements during initial case evaluation.*

Litigation Watch: Eligibility in MDL 3094 requires documented clinical injury, not just adverse side effects, making complete medical records the most important asset any prospective plaintiff can gather.

Explore this too: Drake UMG Lawsuit 2026: Claims, Court Status, Outcome

Ozempic Lawsuit Eligibility Criteria: A State-by-State Consideration

Eligibility criteria under MDL 3094 apply uniformly at the federal pretrial level, but substantive state law governs the underlying product liability claims, and that creates meaningful variation in how individual cases are evaluated.

Each plaintiff's home state law applies to the merits of their claim. States differ on:

• The standard for failure to warn
• Whether the learned intermediary doctrine fully insulates manufacturers from direct patient warning duties
• The availability of punitive damages
• Comparative fault rules that may reduce recovery if a plaintiff's own risk factors contributed to injury

States with notable legal considerations for Ozempic plaintiffs:

*Attorney Insight: Attorneys handling these claims note that because state substantive law applies even within the federal MDL, the state where a plaintiff was prescribed and used Ozempic materially affects litigation strategy and potential outcomes.*

Ozempic Lawsuit Settlement Amount: What the Numbers Look Like

No Ozempic lawsuit settlement has been globally announced as of early 2026. What exists are projected ranges based on the injury tier structure, comparable pharmaceutical MDL settlements, and the damages supported by individual complaints.

Settlement amounts in pharmaceutical mass torts typically stratify by injury severity. MDL 3094 is expected to follow a similar matrix once global negotiations begin in earnest.

Projected compensation ranges by injury tier (pre-settlement estimates only):

These figures are projections. Final settlement values depend on Novo Nordisk's willingness to negotiate, bellwether trial outcomes, and the overall claims population mix.

*Attorney Insight: Attorneys handling these claims note that comparable pharmaceutical MDLs, such as the Zantac litigation and the Xarelto MDL, suggest that early bellwether verdicts disproportionately influence final settlement grids, making trial outcomes in 2026 and 2027 pivotal.*

Ozempic Settlement 2026: Is a Global Deal on the Horizon?

A global Ozempic settlement in 2026 is possible but is not a certainty based on the current litigation posture.

Pharmaceutical defendants typically resist global settlement negotiations until at least one bellwether verdict demonstrates how juries evaluate the plaintiffs' causation theory and damages claims. As of Q1 2026, bellwether trials have not yet commenced.

Factors that could accelerate a 2026 settlement:

• A plaintiff-favorable bellwether verdict in the first trial
• Adverse internal document disclosures from Novo Nordisk's production
• Additional FDA regulatory action on semaglutide labeling
• Volume pressure as docket exceeds 20,000 cases

Factors that could delay settlement:

• Defense motion practice on Daubert challenges to plaintiffs' causation experts
• A defense-favorable bellwether verdict
• Disagreement among plaintiff leadership on settlement allocation criteria
• Ongoing litigation in parallel state court proceedings

*Attorney Insight: Attorneys handling these claims note that Novo Nordisk's financial position, with Ozempic generating over $14 billion in annual global revenue, gives the company capacity to litigate aggressively rather than settle early, making premature settlement assumptions risky for plaintiffs.*

Litigation Watch: No global settlement is confirmed for 2026, and plaintiffs who delay filing while waiting for a settlement announcement risk statute of limitations issues that could bar their claims entirely.

How Much Is the Ozempic Lawsuit Worth Per Plaintiff?

The per-plaintiff value of an Ozempic lawsuit depends on five primary factors that plaintiff attorneys evaluate at initial case intake.

Understanding these factors helps prospective plaintiffs assess their individual case strength before consulting an attorney.

The five factors that determine individual case value:

1. Injury severity and permanence: Permanent gastroparesis requiring a gastric pacemaker or feeding tube yields far higher damages than a resolved diagnosis.
2. Medical expenses: Documented treatment costs, including hospitalization, surgery, specialist fees, and ongoing medication, form the economic damages foundation.
3. Lost income: Plaintiffs who missed significant work or became unable to work have a wage loss damages component.
4. Pain and suffering: Noneconomic damages vary by state caps and jury assessment of quality-of-life impairment.
5. Causation clarity: Cases with a clean causal timeline (Ozempic use followed promptly by diagnosis) are more defensible than cases with significant confounders.

*Attorney Insight: Attorneys handling these claims note that the strongest individual cases combine a severe documented injury, a clean causal timeline, minimal pre-existing GI conditions, and complete medical records from the treating physician.*

How to File an Ozempic Lawsuit in 2026

Filing an Ozempic lawsuit in 2026 involves a specific procedural path that differs from standard civil litigation.

Because MDL 3094 is centralized in the Eastern District of Pennsylvania, cases are not filed individually in a plaintiff's home district and then transferred. Plaintiffs' attorneys typically file directly into the MDL or use the JPML's transfer mechanism for cases initially filed elsewhere.

Step-by-step filing overview:

1. Retain a product liability attorney: The attorney evaluates medical records, confirms injury category eligibility, and assesses case strength.
2. Execute authorization forms: Plaintiff authorizes the attorney to gather all medical, pharmacy, and employment records.
3. Complete the Plaintiff Fact Sheet (PFS): Court-ordered document requiring detailed disclosure of drug use history, diagnosis, treatment, and damages. Incomplete PFS submissions trigger court sanctions in MDL 3094.
4. Case filed into MDL 3094: The complaint is filed in the Eastern District of Pennsylvania or transferred via JPML order.
5. Discovery and case management: Plaintiff's case proceeds through MDL pretrial stages, including deposition scheduling and expert disclosure.
6. Potential remand: If no settlement occurs, the case may be remanded to the plaintiff's home district for trial.

*Attorney Insight: Attorneys handling these claims emphasize that the Plaintiff Fact Sheet in MDL 3094 carries significant procedural consequences for non-compliance, and that careful completion with supporting documentation is non-negotiable.*

Ozempic Lawsuit Filing Deadline: When Does Time Run Out?

The Ozempic lawsuit filing deadline is governed by each state's statute of limitations for product liability claims, not by a single universal MDL deadline.

This distinction is critical. No omnibus filing deadline exists for MDL 3094. Each plaintiff's deadline is calculated individually based on when they were diagnosed and where they reside.

Statute of limitations by state for product liability (selected states):

The discovery rule in most states means the clock starts when a plaintiff knew or reasonably should have known that Ozempic caused their injury, not necessarily from the date they took the drug.

*Attorney Insight: Attorneys handling these claims note that a patient who was diagnosed with gastroparesis years ago but never connected it to Ozempic may still have a viable claim under the discovery rule, but delay in consulting an attorney substantially increases the risk of a limitations bar.*

Ozempic Statute of Limitations: State Rules That Affect Your Claim

The Ozempic statute of limitations question is more complex than most consumer-facing resources acknowledge.

Three doctrines interact to determine whether a claim is timely:

1. The Discovery Rule

The clock starts when the plaintiff discovered, or should have discovered through reasonable diligence, that Ozempic caused their specific injury. A patient hospitalized for gastroparesis who was never told the drug was a cause may have a later start date for the limitations clock.

2. Fraudulent Concealment

If Novo Nordisk is shown to have concealed material safety information from regulators or the public, some courts will toll the statute of limitations for the period of active concealment. This doctrine has been raised in similar pharmaceutical MDLs.

3. Equitable Tolling

Courts sometimes toll the limitations period while a plaintiff is pursuing administrative remedies or when extraordinary circumstances prevented timely filing.

The interaction of these doctrines is state-specific. A plaintiff in California may have a different limitations analysis than one in Florida even if the facts are identical.

*Attorney Insight: Attorneys handling these claims note that the limitations analysis in pharmaceutical failure-to-warn cases often requires review of when published medical literature or regulatory action put plaintiffs on constructive notice of a potential drug connection to their injury.*

Litigation Watch: The statute of limitations is the single most time-sensitive legal issue in the Ozempic litigation, and consulting a product liability attorney to establish your specific deadline is the most urgent practical step any potential plaintiff can take.

Ozempic Product Liability Attorney: Who Handles These Cases

An Ozempic product liability attorney is a trial lawyer with specific experience in pharmaceutical mass torts, MDL procedure, and causation-based personal injury litigation.

This is not a case type for general practitioners or personal injury attorneys without pharmaceutical litigation backgrounds. MDL 3094 requires understanding of FDA regulatory history, clinical pharmacology concepts, complex causation expert testimony, and MDL-specific procedural rules.

Before you go further, consider reading Shein Lawsuit 2026: Claims, Status and Who Qualifies

What to look for in an Ozempic attorney:

• Documented experience with pharmaceutical product liability cases or participation in comparable MDLs
• Familiarity with the Plaintiff Fact Sheet requirements in MDL 3094
• Access to causation experts in gastroenterology and pharmacology
• A contingency fee structure (standard in mass tort cases; no upfront cost to the plaintiff)
• The firm's MDL 3094 leadership committee participation or co-counsel relationships

What attorneys typically do not charge:

In product liability mass tort cases, attorneys almost universally work on a contingency basis. Fees are a percentage of the recovery, typically ranging from 33% to 40%, only paid if the case resolves favorably.

*Attorney Insight: Attorneys handling these claims note that selecting an attorney with active MDL 3094 involvement, rather than one who will refer the case outright to an MDL firm, produces better communication and case management for individual plaintiffs.*

Ozempic Litigation Update 2026: Key Developments to Watch

The Ozempic litigation update for 2026 reflects a case entering its most consequential phase since centralization.

The bellwether selection process, currently underway in MDL 3094, will define the factual and legal battlegrounds for the entire litigation. Judge Pratter's case management orders through late 2025 and into 2026 have focused on narrowing which injury categories and legal theories advance to trial.

Key 2026 developments to monitor:

• Daubert hearings on plaintiffs' causation experts (any exclusion of expert testimony can collapse thousands of individual claims)
• Defense motions for summary judgment in bellwether cases
• FDA communications regarding additional semaglutide label changes
• Parallel state court proceedings in New Jersey and California, which are not subject to MDL 3094 management
• Potential global mediation sessions if bellwether scheduling accelerates

Novo Nordisk's legal posture has been aggressive. The company contests that the scientific evidence establishes a causal link between semaglutide use and permanent gastroparesis at a population level.

*Attorney Insight: Attorneys handling these claims note that the Daubert rulings on general causation experts will be the single most significant legal event in the Ozempic litigation in 2026, as those rulings determine whether plaintiffs can even present causation evidence to a jury.*

Novo Nordisk Sued for Ozempic: The Company's Legal Exposure

Novo Nordisk faces an unprecedented level of legal exposure from the Ozempic litigation, one that creates a genuine strategic challenge for a company whose primary revenue driver is the subject of the lawsuit.

Ozempic and Wegovy collectively generated approximately $14.3 billion in global revenue in 2023, according to Novo Nordisk's public financial disclosures. That revenue scale reflects both the commercial stakes and the company's capacity to fund sustained litigation defense.

Novo Nordisk's legal position:

• The company disputes that clinical evidence supports a causal link between semaglutide and permanent gastroparesis
• Novo Nordisk argues that its FDA-approved labeling adequately disclosed GI risks
• The company contends that pre-existing conditions, comorbidities, and other medications are alternative causes of plaintiffs' GI injuries
• Novo Nordisk has retained major defense counsel and is investing substantially in Daubert expert challenges

The company's defense strategy mirrors that of previous pharmaceutical defendants in major MDLs: contest causation aggressively at the expert stage, limit the number of cases that reach trial, and use bellwether outcomes to calibrate any eventual settlement posture.

*Attorney Insight: Attorneys handling these claims note that Novo Nordisk's internal clinical trial data, now subject to discovery in MDL 3094, represents the most significant potential litigation vulnerability for the company's defense.*

Frequently Asked Questions

What is the Novo Nordisk Ozempic lawsuit about?

The lawsuit alleges Novo Nordisk failed to adequately warn patients and physicians that Ozempic and other semaglutide drugs can cause severe gastrointestinal injuries including gastroparesis and intestinal obstruction.

Plaintiffs claim the company knew about these risks and did not disclose them clearly on the drug's label.

The litigation is centralized in federal court as MDL No. 3094 in the Eastern District of Pennsylvania.

What court handles the Ozempic MDL and who is the judge?

MDL No. 3094 is assigned to the U.S. District Court for the Eastern District of Pennsylvania in Philadelphia.

Judge Gene E.K. Pratter presides over all pretrial proceedings, including discovery, motions, and bellwether selection.

The JPML issued the consolidation order in February 2024 following rapid growth in federally filed semaglutide injury complaints.

Who qualifies to file an Ozempic lawsuit in 2026?

Patients who used Ozempic, Wegovy, or other semaglutide formulations and were diagnosed with gastroparesis, intestinal obstruction, ileus, or cyclic vomiting syndrome may qualify.

The injury must be documented with clinical testing, physician diagnosis, and medical records showing treatment was required.

Patients who experienced only temporary, mild nausea without a formal diagnosis and medical treatment generally do not meet the current threshold for filing.

How much is the Ozempic lawsuit worth per plaintiff?

Individual case values have not been formally set, but projected ranges based on injury severity run from approximately $10,000 for documented mild injuries to $1,000,000 or more for catastrophic cases involving surgery or permanent disability.

No global settlement has been announced as of early 2026, so these figures reflect litigation projections based on comparable MDL outcomes.

Final values will depend heavily on bellwether trial results and how courts rule on causation expert challenges.

What is the filing deadline for the Ozempic lawsuit?

There is no single universal deadline. Each plaintiff's deadline is set by their home state's statute of limitations for product liability claims, typically two to four years from the date of injury discovery.

The discovery rule in most states means the clock starts when a plaintiff knew or reasonably should have known Ozempic caused their condition.

Consulting a product liability attorney immediately is the only reliable way to confirm the specific deadline applicable to an individual case.

What type of attorney handles Ozempic product liability claims?

These cases require a pharmaceutical product liability or mass tort attorney with experience in MDL proceedings and complex causation litigation.

General personal injury attorneys without pharmaceutical MDL experience are typically not equipped to handle the expert discovery and Plaintiff Fact Sheet requirements specific to MDL 3094.

Most attorneys handling these cases work on contingency, meaning no fees are due unless the case resolves favorably.

Closing

The Novo Nordisk Ozempic lawsuit is an active, rapidly expanding federal mass tort with real legal deadlines, demanding procedural requirements, and outcome stakes that vary significantly by individual injury profile. Understanding where the litigation stands is only the beginning.

If you or a family member used Ozempic or a related semaglutide drug and were diagnosed with gastroparesis, intestinal obstruction, or a related gastrointestinal condition that required medical treatment, the time to consult a pharmaceutical product liability attorney is now. Waiting for a settlement announcement before acting creates unnecessary statute of limitations risk.

A qualified attorney who handles pharmaceutical mass torts can evaluate your specific medical record timeline, confirm whether your injury meets MDL 3094's current threshold, and advise on the limitations deadline that applies in your state.

This may also interest you: Select Home Warranty Lawsuit 2026: Full Case Guide